Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Firefly Neuroscience (AIFF) Common Equity (2016 - 2025)

Firefly Neuroscience has reported Common Equity over the past 15 years, most recently at $7.6 million for Q4 2025.

  • Quarterly results put Common Equity at $7.6 million for Q4 2025, up 2136.53% from a year ago — trailing twelve months through Dec 2025 was $7.6 million (up 2136.53% YoY), and the annual figure for FY2025 was $7.6 million, up 2136.53%.
  • Common Equity for Q4 2025 was $7.6 million at Firefly Neuroscience, down from $9.7 million in the prior quarter.
  • Over the last five years, Common Equity for AIFF hit a ceiling of $17.4 million in Q4 2021 and a floor of -$2.8 million in Q3 2024.
  • Median Common Equity over the past 5 years was $2.6 million (2021), compared with a mean of $5.0 million.
  • Biggest five-year swings in Common Equity: plummeted 444.04% in 2024 and later skyrocketed 57711.11% in 2025.
  • Firefly Neuroscience's Common Equity stood at $17.4 million in 2021, then crashed by 112.76% to -$2.2 million in 2022, then surged by 104.9% to $109000.0 in 2023, then plummeted by 444.04% to -$375000.0 in 2024, then soared by 2136.53% to $7.6 million in 2025.
  • The last three reported values for Common Equity were $7.6 million (Q4 2025), $9.7 million (Q3 2025), and $12.1 million (Q2 2025) per Business Quant data.